Ann: Imagion announces HREC approval for Phase I study, page-4

FANTASTIC

Great stuff

7 October 2020
Imagion announces HREC approval for Phase I study
MELBOURNE — Imagion Biosystems (ASX: IBX), a company dedicated to improving healthcare through
the earlier detection of cancer, is pleased to report that it has received approval from the Human Research
Ethics Committee (HREC) for the MagSense™ HER2 Phase I study for metastatic breast cancer. With the
study now approved the Company can proceed with finalising contracts with individual study sites.
Additionally, the Company reports that manufacturing of the MagSense™ HER2 nanoparticle formulation for
the study remains on track, having successfully completed bulk batch production. The company expects to
complete the final step of Good Manufacturing Practice (GMP) compliant packaging of the material on time
to support the start of the study.
Imagion Biosystems Executive Chairman Bob Proulx said, “We are very pleased with our progress and will
now be working diligently with our planned study sites to commence the study this calendar quarter as we
have previously advised.”
-ENDS